Additionally, it has received tentative approval for the 137 mg dosage strength
Read MoreThis new approval allows Mamitra to be marketed in strengths of 150 mg and 440 mg, targeting HER2 overexpressing metastatic breast cancer (MBC), HER2 overexpressing early breast cancer (EBC), and advanced gastric cancer
Read MoreEstablished in 2011 as a 50:50 joint venture for pharmaceutical sales and marketing in India, Bayer has now acquired the remaining 25 per cent stake to secure full ownership of the entity, in accordance with pre-agreed joint venture terms
Read More